223 related articles for article (PubMed ID: 23904864)
1. Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence.
Zerbini CA; McClung MR
Ther Adv Musculoskelet Dis; 2013 Aug; 5(4):199-209. PubMed ID: 23904864
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis.
Duong le T; Leung AT; Langdahl B
Calcif Tissue Int; 2016 Apr; 98(4):381-97. PubMed ID: 26335104
[TBL] [Abstract][Full Text] [Related]
3. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
Stone JA; McCrea JB; Witter R; Zajic S; Stoch SA
Br J Clin Pharmacol; 2019 Jun; 85(6):1072-1083. PubMed ID: 30663085
[TBL] [Abstract][Full Text] [Related]
4. Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis.
Schultz TC; Valenzano JP; Verzella JL; Umland EM
Womens Health (Lond); 2015 Nov; 11(6):805-14. PubMed ID: 26344800
[TBL] [Abstract][Full Text] [Related]
5. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
Lewiecki EM
IDrugs; 2009 Dec; 12(12):799-809. PubMed ID: 19943223
[TBL] [Abstract][Full Text] [Related]
6. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis.
Costa AG; Cusano NE; Silva BC; Cremers S; Bilezikian JP
Nat Rev Rheumatol; 2011 Jun; 7(8):447-56. PubMed ID: 21670768
[TBL] [Abstract][Full Text] [Related]
7. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
Bone HG; McClung MR; Roux C; Recker RR; Eisman JA; Verbruggen N; Hustad CM; DaSilva C; Santora AC; Ince BA
J Bone Miner Res; 2010 May; 25(5):937-47. PubMed ID: 19874198
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
Mukherjee K; Chattopadhyay N
Biochem Pharmacol; 2016 Oct; 117():10-9. PubMed ID: 27106079
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation.
Duong LT
Bonekey Rep; 2012; 1():67. PubMed ID: 23951460
[TBL] [Abstract][Full Text] [Related]
10. Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women.
Pérez-Castrillón JL; Pinacho F; De Luis D; Lopez-Menendez M; Dueñas Laita A
J Osteoporos; 2010 Jun; 2010():. PubMed ID: 20948576
[TBL] [Abstract][Full Text] [Related]
11. [Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis].
Watanabe R; Okazaki R
Clin Calcium; 2014 Jan; 24(1):59-67. PubMed ID: 24369281
[TBL] [Abstract][Full Text] [Related]
12. Potential role of odanacatib in the treatment of osteoporosis.
Ng KW
Clin Interv Aging; 2012; 7():235-47. PubMed ID: 22866001
[TBL] [Abstract][Full Text] [Related]
13. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
14. Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women.
Chapurlat RD
Ther Adv Musculoskelet Dis; 2015 Jun; 7(3):103-9. PubMed ID: 26029271
[TBL] [Abstract][Full Text] [Related]
15. [Cathepsin K antagonists: preclinical and clinical data].
Gamsjäger M; Resch H
Wien Med Wochenschr; 2015 Feb; 165(3-4):65-70. PubMed ID: 25572547
[TBL] [Abstract][Full Text] [Related]
16. Odanacatib for the treatment of osteoporosis.
Boggild MK; Gajic-Veljanoski O; McDonald-Blumer H; Ridout R; Tile L; Josse R; Cheung AM
Expert Opin Pharmacother; 2015; 16(11):1717-26. PubMed ID: 26149759
[TBL] [Abstract][Full Text] [Related]
17. Cathepsin K inhibitors: a novel target but promising approach in the treatment of osteoporosis.
Helali AM; Iti FM; Mohamed IN
Curr Drug Targets; 2013 Dec; 14(13):1591-600. PubMed ID: 23957815
[TBL] [Abstract][Full Text] [Related]
18. New targets for intervention in the treatment of postmenopausal osteoporosis.
Lewiecki EM
Nat Rev Rheumatol; 2011 Sep; 7(11):631-8. PubMed ID: 21931340
[TBL] [Abstract][Full Text] [Related]
19. Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension.
Recker R; Dempster D; Langdahl B; Giezek H; Clark S; Ellis G; de Villiers T; Valter I; Zerbini CA; Cohn D; Santora A; Duong LT
J Bone Miner Res; 2020 Jul; 35(7):1289-1299. PubMed ID: 32119749
[TBL] [Abstract][Full Text] [Related]
20. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength.
Cheung AM; Majumdar S; Brixen K; Chapurlat R; Fuerst T; Engelke K; Dardzinski B; Cabal A; Verbruggen N; Ather S; Rosenberg E; de Papp AE
J Bone Miner Res; 2014 Aug; 29(8):1786-94. PubMed ID: 24643905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
